Skip to main content
. 2022 Jul 28;14(15):3688. doi: 10.3390/cancers14153688

Table 3.

Relationships between SUVmax1, ΔSUVmax%, and clinicopathological parameters.

Parameter No. of Cases
N = 72
SUVmax1 ΔSUVmax% Group A vs. Group B Group C vs. Group D
High
N = 19
Low
N = 53
p-Value High
N = 37
Low
N = 35
p-Value Group A
N = 13
Group B
N = 59
p-Value Group C
N = 43
Group D
N = 29
p-Value
Pathological T factor
T1,2 3 (4%) 0 (0%) 3 (4%) 0.17 1 (1%) 2 (3%) 0.52 0 (0%) 3 (4%) 0.29 1 (1%) 2 (3%) 0.35
T3,4 69 (96%) 19 (26%) 50 (69%) 36 (50%) 33 (46%) 13 (18%) 56 (78%) 42 (58%) 27 (3 8%)
Pathological N factor
Positive 58 (81%) 8 40 (56%) 0.044 29 (40%) 29 (40%) 0.63 12 (17%) 46 (64%) 0.20 35 (47%) 23 (32%) 0.83
Negative 14 (19%) 1 (1%) 13 (18%) 8 (11%) 6 (8%) 1 (1%) 13 (18%) 8 (11%) 6 (8%)
Lymphatic permeation
Positive 64 (89%) 19 (26%) 45 (63%) 0.022 34 (47%) 30 (42%) 0.40 13 (18%) 51 (71%) 0.065 40 (56%) 24 (33%) 0.18
Negative 8 (11%) 0 (0%) 8 (11%) 3 (4%) 5 (7%) 0 (0%) 8 (11%) 3 (4%) 5 (7%)
CA19-9
>512 20 (28%) 9 (13%) 11 (15%) 0.031 12 (17%) 8 (11%) 0.36 8 (11%) 12 (17%) 0.0043 13 (18%) 7 (10%) 0.57
<512 52 (72%) 10 (14%) 42 (58%) 25 (35%) 27 (36%) 5 (7%) 47 (65%) 30 (42%) 22 (31%)
Residual tumor
R0 63 (88%) 16 (22%) 47 (65%) 0.62 32 (44%) 31 (43%) 0.79 10 (14%) 53 (74%) 0.23 38 (53%) 25 (38%) 0.79
R1 9 (13%) 3 (4%) 6 (8%) 5 (7%) 4 (6%) 3 (4%) 6 (8%) 5 (7%) 4 (6%)
Completed adjuvant chemotherapy
Yes 36 (50%) 8 (11%) 28 (39%) 0.42 12 (17%) 24 (33%) 0.0019 4 (6%) 32 (44%) 0.12 16 (22%) 20 (28%) 0.0076
No 36 (50%) 11 (15%) 25 (38%) 25 (38%) 11 (15%) 9 (13%) 27 (38%) 27 (38%) 9 (13%)

SUV, standardized uptake value; PPV, positive predictive value; NPV, negative predictive value; group A, high SUVmax1 and high ΔSUVmax%; group B, and others except A; group C, SUVmax1 and/or ΔSUVmax%; group D, and others except C. Values in bold are statistically significant.